These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
248 related articles for article (PubMed ID: 31951177)
1. MiR-143 Inhibits Osteoclastogenesis by Targeting RANK and NF-κB and MAPK Signaling Pathways. He X; Zhu L; An L; Zhang J Curr Mol Pharmacol; 2020; 13(3):224-232. PubMed ID: 31951177 [TBL] [Abstract][Full Text] [Related]
2. Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways. Li C; Yang Z; Li Z; Ma Y; Zhang L; Zheng C; Qiu W; Wu X; Wang X; Li H; Tang J; Qian M; Li D; Wang P; Luo J; Liu M J Bone Miner Res; 2011 Mar; 26(3):644-56. PubMed ID: 20814972 [TBL] [Abstract][Full Text] [Related]
3. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells. Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653 [TBL] [Abstract][Full Text] [Related]
4. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT. Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828 [TBL] [Abstract][Full Text] [Related]
5. I-BET151 suppresses osteoclast formation and inflammatory cytokines secretion by targetting BRD4 in multiple myeloma. Guo NH; Zheng JF; Zi FM; Cheng J Biosci Rep; 2019 May; 39(5):. PubMed ID: 30455393 [No Abstract] [Full Text] [Related]
6. I‑BET151 inhibits osteoclastogenesis via the RANKL signaling pathway in RAW264.7 macrophages. Cheng J; Zheng J; Guo N; Zi F Mol Med Rep; 2017 Dec; 16(6):8406-8412. PubMed ID: 28983590 [TBL] [Abstract][Full Text] [Related]
8. Tereticornate A suppresses RANKL-induced osteoclastogenesis via the downregulation of c-Src and TRAF6 and the inhibition of RANK signaling pathways. Liu T; Jiang L; Xiang Z; Li J; Zhang Y; Xiang T; Wang W; Li X; Jia Y; Huang X; Lu X; Xu H; Wang X; Sheng J Biomed Pharmacother; 2022 Jul; 151():113140. PubMed ID: 35605290 [TBL] [Abstract][Full Text] [Related]
9. Guaiacol suppresses osteoclastogenesis by blocking interactions of RANK with TRAF6 and C-Src and inhibiting NF-κB, MAPK and AKT pathways. Zhi X; Fang C; Gu Y; Chen H; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J J Cell Mol Med; 2020 May; 24(9):5122-5134. PubMed ID: 32185887 [TBL] [Abstract][Full Text] [Related]
10. Icariin abrogates osteoclast formation through the regulation of the RANKL-mediated TRAF6/NF-κB/ERK signaling pathway in Raw264.7 cells. Kim B; Lee KY; Park B Phytomedicine; 2018 Dec; 51():181-190. PubMed ID: 30466615 [TBL] [Abstract][Full Text] [Related]
11. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways. Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253 [TBL] [Abstract][Full Text] [Related]
12. Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways. Chen K; Yan Z; Wang Y; Yang Y; Cai M; Huang C; Li B; Yang M; Zhou X; Wei X; Yang C; Chen Z; Zhai X; Li M Biomed Pharmacother; 2020 Jun; 126():110067. PubMed ID: 32272431 [TBL] [Abstract][Full Text] [Related]
13. (-)-Epigallocatechin-3-gallate inhibits osteoclastogenesis by blocking RANKL-RANK interaction and suppressing NF-κB and MAPK signaling pathways. Xu H; Liu T; Jia Y; Li J; Jiang L; Hu C; Wang X; Sheng J Int Immunopharmacol; 2021 Jun; 95():107464. PubMed ID: 33677256 [TBL] [Abstract][Full Text] [Related]
15. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways. Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759 [TBL] [Abstract][Full Text] [Related]
16. 12-O-tetradecanoylphorbol-13-acetate (TPA) inhibits osteoclastogenesis by suppressing RANKL-induced NF-kappaB activation. Wang C; Steer JH; Joyce DA; Yip KH; Zheng MH; Xu J J Bone Miner Res; 2003 Dec; 18(12):2159-68. PubMed ID: 14672351 [TBL] [Abstract][Full Text] [Related]
17. Current Understanding of RANK Signaling in Osteoclast Differentiation and Maturation. Park JH; Lee NK; Lee SY Mol Cells; 2017 Oct; 40(10):706-713. PubMed ID: 29047262 [TBL] [Abstract][Full Text] [Related]
18. Neobavaisoflavone inhibits osteoclastogenesis through blocking RANKL signalling-mediated TRAF6 and c-Src recruitment and NF-κB, MAPK and Akt pathways. Chen H; Fang C; Zhi X; Song S; Gu Y; Chen X; Cui J; Hu Y; Weng W; Zhou Q; Wang Y; Wang Y; Jiang H; Li X; Cao L; Chen X; Su J J Cell Mol Med; 2020 Aug; 24(16):9067-9084. PubMed ID: 32604472 [TBL] [Abstract][Full Text] [Related]
19. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways. Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053 [TBL] [Abstract][Full Text] [Related]
20. (+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation. Chiou WF; Huang YL; Liu YW PLoS One; 2014; 9(2):e89159. PubMed ID: 24558484 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]